bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 9,900 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $149.58, for a total value of $1,480,842.00. Following the completion of the transaction, the insider now directly owns 28,798 shares of the company’s stock, valued at approximately $4,307,604.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of bluebird bio, Inc. (BLUE) opened at $156.90 on Thursday. bluebird bio, Inc. has a 52-week low of $56.80 and a 52-week high of $164.80.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm’s revenue was up 397.4% compared to the same quarter last year. During the same period last year, the business posted ($2.07) EPS. sell-side analysts forecast that bluebird bio, Inc. will post -6.68 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://ledgergazette.com/2017/11/16/jeffrey-t-walsh-sells-9900-shares-of-bluebird-bio-inc-blue-stock.html.
Institutional investors and hedge funds have recently modified their holdings of the company. QS Investors LLC lifted its holdings in shares of bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of bluebird bio by 454.2% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 813 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares during the last quarter. Turner Investments LLC purchased a new stake in shares of bluebird bio during the 2nd quarter valued at $184,000. Finally, Biondo Investment Advisors LLC purchased a new stake in shares of bluebird bio during the 3rd quarter valued at $203,000.
A number of equities analysts have recently weighed in on the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $88.00 price objective on shares of bluebird bio in a research note on Friday, August 11th. BidaskClub lowered bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Morgan Stanley raised bluebird bio from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 3rd. Evercore ISI raised bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price objective for the company in a research note on Monday, October 16th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $186.00 target price on shares of bluebird bio in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $131.05.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.